ProShares Ultra NASDAQ Biotechnology
BIB
25 hedge funds and large institutions have $8.16M invested in ProShares Ultra NASDAQ Biotechnology in 2023 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 7 increasing their positions, 8 reducing their positions, and 0 closing their positions.
13% more call options, than puts
Call options by funds: $1.6M | Put options by funds: $1.42M
4% more funds holding
Funds holding: 24 → 25 (+1)
2.56% less ownership
Funds ownership: 11.28% → 8.72% (-2.6%)
13% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 8
30% less capital invested
Capital invested by funds: $11.6M → $8.16M (-$3.46M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JF
Jump Financial
Chicago,
Illinois
|
+$234K |
| 2 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$89.3K |
| 3 |
TFA
Toth Financial Advisory
Leesburg,
Virginia
|
+$44.9K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$28.9K |
| 5 |
CG
Cutler Group
San Francisco,
California
|
+$22K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$1.71M |
| 2 |
IMC Chicago
Chicago,
Illinois
|
-$1.65M |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
-$144K |
| 4 |
CIA
Capital Investment Advisors
Atlanta,
Georgia
|
-$34.4K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$22.9K |
BIB Hedge Fund Activity: Q2 2023 in Review
25 of the 6,383 institutional investors tracked by Wall St. Rank reported a position in ProShares Ultra NASDAQ Biotechnology (BIB) for Q2 2023, worth a combined $8.16M — down 30% from $11.6M a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new BIB positions and 0 closed out — a net gain of 1 holder — while 7 added to existing stakes and 8 trimmed.
The largest buyer was Jump Financial, adding an estimated $234K. The largest seller was Susquehanna International Group, cutting an estimated $1.71M.
- 25 institutional investors held ProShares Ultra NASDAQ Biotechnology (BIB) as of Q2 2023, up from 24 in Q1 2023.
- Funds reported $8.16M of ProShares Ultra NASDAQ Biotechnology stock for Q2 2023, down 30% quarter-over-quarter.
- 1 fund opened new ProShares Ultra NASDAQ Biotechnology positions in Q2 2023 and 0 closed out, a net change of +1 holder.
- The largest ProShares Ultra NASDAQ Biotechnology buyer in Q2 2023 was Jump Financial, an estimated $234K added.
- The largest ProShares Ultra NASDAQ Biotechnology seller in Q2 2023 was Susquehanna International Group, an estimated $1.71M sold.
Based on aggregated 13F filings for Q2 2023.